Formulations of human Anti-rankl antibodies, and methods of using the same

TW202631193APending Publication Date: 2026-08-01AMGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Filing Date
2018-04-27
Publication Date
2026-08-01

Smart Images

  • Figure TWG2TA001070811_001
    Figure TWG2TA001070811_001
  • Figure TWG2TA001070811_002
    Figure TWG2TA001070811_002
  • Figure TWG2TA001070811_003
    Figure TWG2TA001070811_003
Patent Text Reader

Abstract

Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.
Need to check novelty before this filing date? Find Prior Art